Acadian Asset Management
AMLX icon

Acadian Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Acadian Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-254,328
Closed -$3.07M – 2010
2025
Q4 		$3.07M Sell
254,328
-113,003
-31% -$1.53M 0.01% 792
2025
Q3 		$4.99M Sell
367,331
-201,752
-35% -$1.9M 0.01% 643
2025
Q2 		$3.65M Buy
569,083
+326,976
+135% +$1.59M 0.01% 664
2025
Q1 		$855K Sell
242,107
-369,819
-60% -$1.32M ﹤0.01% 970
2024
Q4 		$2.31M Sell
611,926
-1,158,271
-65% -$5.45M 0.01% 730
2024
Q3 		$5.73M Buy
1,770,197
+558,580
+46% +$1.26M 0.02% 470
2024
Q2 		$2.3M Buy
+1,211,617
New +$2.35M 0.01% 714

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Acadian Asset Management's AMLX Position: Q1 2026 in Review

Acadian Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 254,328 shares — an estimated $3.07M sold.

Acadian Asset Management first reported a position in AMLX in Q2 2024 and held it in 7 quarters. The position peaked at $5.73M in Q3 2024. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Acadian Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 254,328 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.07M.
  • Acadian Asset Management first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Acadian Asset Management's Amylyx Pharmaceuticals position peaked at $5.73M in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.